The senescence-associated secretory phenotype (SASP) encompasses a complex cocktail of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α), chemokines (CXCL1, CCL2, CCL5), growth factors (VEGF, PDGF), and matrix metalloproteinases (MMP-1, MMP-3) that varies in composition and intensity depending on the senescence inducer and cell type. This hypothesis proposes that the therapeutic decision between SASP suppression (using JAK1/2 inhibitors such as ruxolitinib or baricitinib) and senolytic elimi
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.60
Evidence
0.75
Novelty
0.55
Feasibility
0.50
Impact
0.65
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.40
KG Connect
0.50
Score Breakdown
Dimension
SASP Transient Suppression vs.
Mechanistic
0.600
Evidence
0.750
Novelty
0.550
Feasibility
0.500
Impact
0.650
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.400
KG Connect
0.500
Evidence
SASP Transient Suppression vs. Senolytic Elimination: A Ther